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Background: Resveratrol is a polyphenolic phytoalexin that has been shown to exhibit osteoprotective and
chondroprotective properties. We examine the effects of resveratrol treatment on bone and cartilage tissue of
obese, diabetic ob/ob mice.
Methods: Eight-week-old ob/ob and lean control mice were given trans-resveratrol at an oral dose of 25 mg/kg for
3 weeks. Histomorphometric and cross-sectional-geometric variables were analyzed.
Results: Ob/ob mice in our study exhibit significantly reduced femoral length, resistance to loading, and tibial
growth plate total area and calcified area than lean controls (P < 0.05). Resveratrol treatment significantly increased
cortical area in both ob/ob and control mice, but did not improve cross-sectional indicators of resistance to bending.
Resveratrol treatment also reduced tibial length and calcified growth plate cartilage area in comparison to untreated
mice (P < 0.05).
Conclusion: Resveratrol treatment of ob/ob mice had mixed effects on bone histomorphometry at the femoral
midshaft. Treatment increased cortical area but decreased bone length.
Keywords: Leptin, Resveratrol, Growth plate, Cross-sectional geometryIntroduction
Obesity has been identified as an important risk factor
in the development of disorders that affect bone health,
including type 2 diabetes. According to the World
Health Organization, approximately 85% of individuals
diagnosed with type 2 diabetes are obese. Type 2 dia-
betics also have elevated rates of bone fracture, particu-
larly at sites characterized by the presence of abundant
cortical bone, such as limb bones [1-3]. The mechanism
of fracture appears to be primarily structural in nature.
Diabetes-related loss of cortical bone, coupled with inad-
equate compensatory trabecular growth, may reduce
resistance to bending loads and leads to increased inci-
dence of bone fracture [4,5].
The relationship among obesity, bone health, and dia-
betes is extremely complex. One significant factor in this
relationship is the adipokine leptin, which is secreted in
response to insulin and aids in the regulation of body* Correspondence: jploch@midwestern.edu
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unless otherwise stated.mass and bone mass homeostasis [6,7]. Insulin resist-
ance in type 2 diabetes is strongly associated with leptin
levels, which in turn is associated with obesity [8,9].
Serum leptin levels have been demonstrated to be
depressed in type 2 diabetics with low bone mineral
density, putting them at higher risk for bone fracture
[4,5]. Similarly, mice of the leptin-deficient ob/ob strain
exhibit hyperglycemia and hyperinsulinemia consistent
with the phenotype of type 2 diabetes and have reduced
limb bone mass and length [9,10]. Leptin-deficiency in
ob/ob mice also reduces bone strength via its inhibitory
effect on growth plate cartilage metabolism [11]. Thus,
reduced bone strength observed with type 2 diabetes
may be related to the role leptin plays in the regulation
of bone mass.
Resveratrol (3,5,4’-trihydroxystilbene) is a naturally-
occurring phytoestrogen that has been shown to exhibit
many properties that benefit health, including bone
health [12]. Resveratrol selectively binds to estrogen re-
ceptors on bone and cartilage cells in vitro to upregulate
the expression of genes that have osteoprotective and
chondroprotective effects [13-15]. The interaction ofThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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sensitivity in diabetics, as well as bone health [16,17].
The aim of this study is to investigate the effects of res-




The study utilized male mice of the strain B6.V-Lep/J
(000632; Jackson Laboratories, Bar Harbor, ME). Leptin-
deficient ob/ob mice of this strain are a commonly used
animal model for studying diabetes and obesity. They
exhibit chronically elevated glucose and insulin levels,
are phenotypically similar to humans with type 2 dia-
betes, and demonstrate severe obesity. However, the
hyperglycemia in ob/ob mice is transient, terminating
between the ages of 14 and 16 weeks. To ensure the
mice in our experiment were hyperglycemic, our experi-
ment utilized mice aged 8 weeks. Lean ob/+ mice were
used as controls. These heterozygous mice have the ob
allele but do not exhibit the type 2 diabetes phenotype
of ob/ob mice. Therefore, comparisons between these
genotypes allow for clearer elucidation of the effects of
resveratrol treatment while other biological factors re-
main similar. All mice were fed ad libitum and housed
two per cage in a facility with a 12-hour light/dark cycle
and temperature held constant at 22°C. The study was
approved by the Midwestern University Institutional
Animal Care and Use Committee. Care of all animals
used in the study was in accordance with the recom-
mendations in The Guide for the Care and Use of
Laboratory Animals, National Institutes of Health, 2011.
Experimental design
Mice were divided into groups of lean control, lean
resveratrol-treated, obese control, and obese resveratrol-
treated. Trans-resveratrol, the active form of resveratrol,
was administered at 25 mg/kg in a volume of 0.5 to
0.75 ml once daily for 21 days via oral gavage. This dose
is higher than would be attained through a normal diet
has been shown to have good bioavailability following
oral administration in mice [18]. Lower doses of resvera-
trol, such as 1 mg/kg, have been shown to have no effectTable 1 Two-way ANOVA of cross-sectional properties of the
Lean (n = 11) Lean + RES
(n = 12)
Obese (n = 14) O
(
Femur length (mm) 15.4 ± 0.7 15.3 ± 1.2 13.9 ± 0.8 1
Ct.Ar. (mm2) 2.8 ± 0.1 3.3 ± 0.2 2.8 ± 0.1 3
Imax (×10
−2 mm4) 10.4 ± 1.6 11.9 ± 1.7 9.2 ± 0.9 9
Imin (×10
−2 mm4) 7.2 ± 1.6 9.7 ± 2.2 5.5 ± 0.6 7
J (×10−2 mm4) 17.5 ± 1.7 21.6 ± 2.2 14.7 ± 0.6 1on cortical bone histomorphometry [19]. The timing
and duration of the treatment period coincides with the
period during which ob/ob mice exhibit the type 2 dia-
betes phenotype. Resveratrol was mixed with a 1% solu-
tion of methylcellulose (Sigma-Aldrich, MO, USA) to
form a colloid to facilitate administration. Control mice
were fed with vehicle alone. During the study, there were
no signs of gastrointestinal stress, changes in behavior,
changes in weight, or other indicators that the treatment
was not being tolerated. The specific numbers of each
bone collected for each treatment group are listed in
Tables 1 and 2. After three weeks of treatment, mice
were sacrificed with CO2 asphyxiation and the hind limb
bones dissected.
Femoral midshaft cross-sectional geometry
Following sacrifice, femurs were removed, cleaned of
soft tissue, and their lengths measured using digital cali-
pers. The bones were then fixed in formalin, dehydrated
in alcohol, and embedded in methyl methacrylate
(Polysciences, Warrington, PA, USA). A single section
approximately 150 μm in thickness was taken at the
midshaft in the transverse plane of each femur using a
low-speed saw (Isomet; Buehler, Lake Bluff, IL, USA).
The sections were mounted on glass slides and manually
ground with 600 grit abrasive paper to a thickness of
75 μm and imaged at 4x magnification with an Eclipse
55i microscope (Nikon, Inc., USA). The images were
converted to black and white using the threshold func-
tion of ImageJ v1.44 and the MomentMacroJ plugin
(written by M. Warfel and modified by S. Serafin) was
used to calculate the cortical area (Ct.Ar.), maximum
second moment of area (Imax), minimum second mo-
ment of area (Imin), and polar second moment of inertia
(J). These geometric properties of bone in cross-section
are used as surrogate indices of resistance to mechanical
deformation during loading and assume bone material
properties are similar among treatment groups. These
surrogates are commonly used in analyses of bone
strength and are derived from beam models employed
by engineers [20,21]. Beam models are used to calculate
mechanical characteristics from the geometric distribu-








3.7 ± 0.9 0.01 0.14 0.46
.0 ± 0.1 0.04 0.01 0.57
.8 ± 1.3 0.01 0.43 0.73
.6 ± 1.1 0.03 0.13 0.88
7.5 ± 0.8 0.02 0.02 0.63
Table 2 Two-way ANOVA of tibia length and proximal growth plate histomorphometry (mean ± SE)
Lean (n = 7) Lean + RES
(n = 8)







Tibia length (mm) 18.0 ± 0.09 17.69 ± 0.08 17.2 ± 0.07 16.92 ± 0.09 0.01 0.01 0.08
Tt.Ar (mm2) 0.36 ± 0.03 0.40 ± 0.02 0.36 ± 0.01 0.30 ± 0.02 0.02 0.89 0.03
B.Ar (mm2) 0.12 ± 0.02 0.14 ± 0.02 0.11 ± 0.01 0.09 ± 0.01 0.04 0.76 0.20
B.Ar/Tt.Ar (%) 33.4 ± 2.85 35.1 ± 2.05 30.8 ± 1.96 32.5 ± 1.69 0.25 0.44 0.98
Tt.GPl.Ar (mm2) 0.70 ± 0.02 0.67 ± 0.01 0.56 ± 0.01 0.37 ± 0.0 0.05 0.98 0.09
Md.GPl.Ar (mm2) 0.12 ± 0.01 0.10 ± 0.01 0.08 ± 0.03 0.05 ± 0.01 0.01 0.05 0.34
Md.GPl.Ar/Tt.GPl.Ar (%) 0.12 ± 0.01 0.10 ± 0.01 0.08 ± 0.03 0.05 ± 0.01 0.04 0.04 0.18
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to its width, such as limb bone.
Cortical area is indicative of resistance to compression,
Imax and Imin reflect bending stiffness, and J approxi-
mates torsional stiffness.
Proximal tibia histomorphometry
Immediately following sacrifice, tibias were harvested
and their lengths measured using digital calipers. Tibias
were then fixed and decalcified in solution for 4 days
(Decalcifier II, Surgipath, Richmond, IL, USA), frozen in
liquid nitrogen, and cryosectioned in the mid-coronal
plane at a thickness of 12 μm. Sections were stained with
toluidine blue and aqueous fast green (Sigma Aldrich,
St. Louis, MO) and imaged at 40x magnification with an
Eclipse 55i microscope (Nikon, Inc., USA).
ImageJ v1.44 was used to measure the total area of
epiphyseal tissue (Tt. Ar) of the proximal epiphysis of
the tibia. Tt.Ar is a measure of the total area of bone
and marrow tissue in the epiphysis. Area of epiphyseal
bone tissue (B.Ar) and the ratio of epiphyseal bone area to
total area (B.Ar/Tt.Ar) were also collected. For all measure-
ments of epiphyseal bone in the proximal tibia, the entire
epiphysis was evaluated, not just a region of interest.
Measurements were also taken at the proximal epi-
physeal growth plate of the tibia. Total area of cartilage
in the growth plate (Tt.GPl.Ar), area of calcified cartilage
in the growth plate (Md.GPl.Ar), and ratio of total to
calcified area of the growth plate (Md.GPl.Ar/Tt.GPl.Ar)
were measured. Measurements of growth plate tissue
area were preferred over measurements of thickness be-
cause the growth plate borders were highly irregular,
making thickness measurements difficult to reproduce
reliably. The area measurements were taken for the
entire growth plate, thus area of calcified cartilage is the
area along the entire length of growth plate that was
calcified. Bone, cartilage, and calcified cartilage were dis-
tinguished during measurement by their different stain-
ing properties. Threshold values for each staining color
were used to differentiate between calcified and non-
calcified cartilage tissue.Statistical analysis
All data are presented as means ± standard error of
the mean (SE). The effects of resveratrol treatment on
lean and obese mice were tested using two-way ana-
lysis of variance (ANOVA). Because bending strains
are proportional to both body mass and bone length
[21], body mass and femur length were used as covari-
ates for analyses of cross-sectional geometric data. All
statistics were performed using SPSS 19 software
(IBM, USA). Statistical significance was set at P < 0.05
for all analyses.
Results
Resveratrol treatment significantly reduces body mass
Figure 1 shows body mass comparisons among treat-
ment groups at the time of sacrifice. As expected, there
was a genotype main effect. Lean ob/+ mice had signifi-
cantly lower body mass than obese ob/ob mice (F = 81.5;
P = 0.01). There was also a treatment group main effect.
Mice treated with resveratrol exhibited significantly
lower body mass than vehicle-treated controls (F = 4.4;
P = 0.04). No interaction was found between genotype
and treatment group. No differences in body mass were
observed at 8, 9, or 10 weeks of age.
Resveratrol treatment marginally improves cross-sectional
geometric indicators of resistance to loading in ob/ob mice
Table 1 shows results of the two-way ANOVA for femur
length and femoral midshaft cross-sectional geometric
properties. Femur length was significantly reduced in
obese mice in comparison to lean mice (F = 59.9 P < 0.01).
No effect on femur length was found with resveratrol
treatment (P > 0.05). Ct.Ar. and J differed significantly
between obese and lean mice (F = 4.3; P = 0.04 and F = 5.6;
P = 0.02 respectively), and with resveratrol treatment
(F = 6.1; P = 0.01 and F = 5.3; P = 0.02 respectively).
Conversely, resveratrol treatment had no effect on
Imax and Imin (P > 0.05), but these variables differed signifi-
cantly between ob/ob and ob/+ mice. Ob/ob mice exhib-
ited reduced Imax and Imin when compared to ob/+ mice
(F = 6.6; P = 0.01 and F = 4.9; P = 0.03 respectively).
Figure 1 Comparison of body mass among treatment groups. * P < 0.05 lean control vs. obese control; ** P < 0.05 lean resveratrol-treated vs.
obese resveratrol-treated.
Cooley et al. Journal of Diabetes & Metabolic Disorders  (2015) 14:10 Page 4 of 7Resveratrol treatment reduces tibia length and tissue area
in the proximal tibial epiphysis
Summary statistics of tibia length and histomorphometry
are presented in Table 2. Obese mice had significantly
shorter tibias than lean mice (F = 77.3; P < 0.01). Tibial
length decreased by 4% with resveratrol treatment
(F = 12.6; P = 0.01). Both Tt.Ar and B.Ar were reduced in
obese mice in comparison to lean mice (F = 6.5; P = 0.02
and F = 4.9; P = 0.04 respectively), but neither was affectedFigure 2 Photo micrographs of the proximal tibial growth plate of lea
obese resveratrol-treated (D) mice. Obese mice had growth plate chond
mice. Mice treated with resveratrol had significantly greater calcified cartila
green, 20x magnification. Scale bar = 100 μm. * calcified cartilage; ** bone.by resveratrol treatment (P > 0.05). There was also no dif-
ference in B.Ar/Tt.Ar between lean and obese mice or
between resveratrol and vehicle-treated mice (P > 0.05).
Resveratrol treatment decreases the area of calcified
cartilage in the proximal tibia growth plate
Figure 2 shows growth plate cartilage of the proximal
tibia in lean and obese mice. Articular chondrocytes
were much more disorganized in ob/ob mice than leann control (A), lean resveratrol-treated (B), obese control (C), and
rocytes that appeared to be more disorganized than those of lean
ge areas than controls (P < 0.05). Toluidine blue and aqueous fast
Cooley et al. Journal of Diabetes & Metabolic Disorders  (2015) 14:10 Page 5 of 7mice in both the control and resveratrol-treated groups.
Table 2 depicts results of the two-way ANOVA for tibial
histomorphometric comparisons. Obese mice had sig-
nificantly reduced Md.GPl.Ar and Tt.GPl.Ar in compari-
son to lean mice (F = 12.7; P < 0.01 and F = 3.9; P = 0.05
respectively). Mice treated with resveratrol exhibited a
smaller Md.GPl.Ar than controls (F = 4.0; P = 0.05), as
well as a reduced Md.GPl.Ar/Tt.GPl.Ar ratio (F = 5.0;
P = 0.04).
Discussion
Leptin is an adipokine with many known functions, in-
cluding the regulation of bone mass. Although early in-
vestigations into the effects of leptin on bone mass were
incongruous [9,22-24], recent papers suggest leptin
upregulates the expression of genes involved in ossifica-
tion and bone mineralization and down-regulates bone
resorption [25,26]. Consequently, ob/ob mice, which are
leptin deficient, have significantly reduced bone mass
and rates of bone accrual, while ob/ob mice treated with
leptin regain osteogenic abilities [27]. In support of these
findings, our study shows that ob/ob mice have shorter
limb bones and reduced cortical area at the femoral mid-
shaft than lean controls. Of note, ob/ob mice in our
study also exhibited significantly reduced tibial growth
plate cartilage area and area of growth plate calcification
than lean controls, possibly because the mice in our
study were still in the active skeletal growth stage of
development. Leptin has been previously shown to in-
crease chondrocyte proliferation and differentiation, re-
duce collagen expression by chondrocytes, and promote
angiogenesis in the vicinity of hypertrophic chondrocytes
[11,28,29]. These findings, combined with our own,
strongly suggest leptin deficiency impairs growth of limb
bones primarily by acting on growth plate cartilage.
Our study also shows femurs of ob/ob mice have sig-
nificantly reduced cross-sectional geometric indices of
bone strength. Femurs of ob/ob mice in our study
exhibit less than half the resistance to bending and a
quarter the resistance to torsion of matched controls.
Similarly, ob/ob mice have previously been shown to
possess significantly reduced bone mineral density, bone
mineral content, and cortical thickness of limb bones
due to a reduction in the rate of bone formation
[9,27,30] and an increase in bone resorption [27,30].
Low serum leptin levels have been directly associated
with low mineral density in type 2 diabetics, leading to
high fracture rate of limb bones [4,5,31]. Fracture rates
of limb bones can be as much as twice that of healthy
individuals, even when controlling for other risk factors
of bone fracture [32,33]. The results of our study support
the hypothesis that leptin deficiency-related diabetes is
associated with poor bone strength and may contribute
to the high fracture rates found in obese diabetics.Resveratrol treatment did little to improve cross-
sectional geometric indices of bone strength in the mice
in our study. In vitro studies have demonstrated that
resveratrol upregulates the expression of genes that pro-
mote osteogenesis [13,14] to increase osteoblast prolifer-
ation and differentiation [34,35]. Other studies have
shown that bone resorption is down-regulated by resver-
atrol primarily through the suppression of genes that
promote osteoclastogenesis [36]. We found resveratrol
treatment at a dose of 25 mg/kg does significantly in-
crease femoral cortical area, which is an indicator of
resistance to compression, and J, which is an indicator of
resistance to torsion. However, resveratrol treatment did
not increase resistance to bending in either ob/ob mice
or lean controls. These data suggest the addition of bone
that resulted in large changes in the area and shape of
the bone, but only small increases along the bending
axes. Because long bone fractures are primarily the re-
sult of bending loads, resveratrol treatment may not be a
viable therapeutic intervention to reduce fracture rates
in diabetics, although further investigation is required to
determine if different doses or methods of administra-
tion may be beneficial.
Resveratrol treatment significantly reduced the area of
calcified cartilage in the proximal tibial growth plate of
both lean and obese mice in our study. We also found
resveratrol treatment reduced tibial length in both lean
and obese mice. This was contrary to what we expected.
Previous studies have shown resveratrol treatment re-
duces chondrocyte apoptosis and the expression of
matrix-degrading proteins, which suggest resveratrol ex-
hibits chondroprotective properties [37,38]. However,
resveratrol treatment has been shown to suppress the re-
lease of angiogenic factors responsible for facilitating
calcification of growth plate cartilage [39]. It is possible
the reduction in calcified area of the growth plate is due
to the attenuating effects of resveratrol on angiogenic
factors, although more research in necessary to investi-
gate the precise mechanism. Further study is necessary
to determine if there is a direct associate between resver-
atrol treatment and an increase in release of angiogenic
factors by growth plate chondrocytes.
Overall, the results of this study suggest leptin defi-
ciency is strongly associated with reduced limb bone
length and resistance to loading in obese, diabetic ob/ob
mice, which may help explain the increased fracture risk
in diabetic patients. Our findings further suggest resver-
atrol treatment does not significantly ameliorate the
negative effects of leptin deficiency. While resveratrol
treatment may increase bone mass at the femoral mid-
shaft, it does so in a manner that does not provide a sig-
nificant improvement in resistance to bending, at least
in the dose used in this investigation. Resveratrol may
also lead to a significant decrease in bone length by
Cooley et al. Journal of Diabetes & Metabolic Disorders  (2015) 14:10 Page 6 of 7inhibiting calcification of growth plate cartilage as indi-
cated by the reduction we found in the area of calcified
cartilage of the growth plate. However, more research is
necessary to determine how applicable our findings are
to diabetic humans given ob/ob mice exhibit the diabetic
phenotype only during growth (i.e., before week 14)
while most diabetic humans are adult. Additional study
is also necessary to assess whether leptin deficiency
adversely affects bone material properties in a manner
that contributes to changes in material stiffness to in-
crease fracture risk. It could be that a reduction in bone
quality also affects bone strength.
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